Dr. Neil Fleshner, MD
Claim this profileUniversity Health Network
Studies Prostate Cancer
Studies Metabolic Syndrome
5 reported clinical trials
13 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
metastatic
localized
2Metabolic Syndrome
metastatic
localized
testosterone
Affiliated Hospitals
Clinical Trials Neil Fleshner, MD is currently running
Genomic Biomarker-Selected Therapy
for Prostate Cancer
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib. The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
Recruiting1 award Phase 210 criteria
Photodynamic Therapy
for Prostate Cancer
This trial tests a new treatment using lasers and a special drug for men whose prostate cancer has returned. The laser activates the drug to destroy cancer cells.
Recruiting2 awards Phase 1 & 2
More about Neil Fleshner, MD
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Neil Fleshner, MD has experience with
- Metformin
- Luteinizing Hormone-releasing Hormone Agonist (LHRHa)
- Apalutamide
- Prednisone 5mg Tab
- Docetaxel
- Niraparib 100mg Oral Capsule
Breakdown of trials Neil Fleshner, MD has run
Prostate Cancer
Metabolic Syndrome
Klinefelter Syndrome and Triple X Syndrome.
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Neil Fleshner, MD specialize in?
Neil Fleshner, MD focuses on Prostate Cancer and Metabolic Syndrome. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are metastatic.
Is Neil Fleshner, MD currently recruiting for clinical trials?
Yes, Neil Fleshner, MD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Neil Fleshner, MD has studied deeply?
Yes, Neil Fleshner, MD has studied treatments such as Metformin, Luteinizing hormone-releasing hormone agonist (LHRHa), Apalutamide.
What is the best way to schedule an appointment with Neil Fleshner, MD?
Apply for one of the trials that Neil Fleshner, MD is conducting.
What is the office address of Neil Fleshner, MD?
The office of Neil Fleshner, MD is located at: University Health Network, Toronto, Ontario M5G 2C4 Canada. This is the address for their practice at the University Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.